

Gland Pharma Low BP generic receives FDA approval

Vasopressin is a short-acting therapy indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.



Mumbai: Injectables maker Gland Pharma announced that its low blood pressure drug Vasopressin has received approval from the US FDA.

Vasopressin is a short-acting therapy indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.

In addition to the 40 Units per 100 mL version, the drugmaker's 20 Units per 100 mL (0.2 Units per mL) RTU Vials has been granted a tentative approval by the FDA.

The product is therapeutically equivalent to the reference listed drug (RLD), Vasostrict marketed by PH Health and as of June this year the drug has an estimated moving annual turnover (MAT) of \$45 million (around Rs 380 crore) in the US.

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/gland-pharmas-vasopressin-receives-fda-approval-for-low-blood-pressure-treatment/123543715>